Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir [Camvia] for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Maribavir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Shire; ViroPharma
- 02 Jun 2012 Additional locations added as reported by European Clinical Trials Database.
- 20 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.